Physiologic MR Imaging of Salivary Gland Tumors
ConditionSalivary Gland Tumor
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Possess a salivary gland lesion of 1cm3 size
Have no prior history of treatment for salivary gland lesion
Disqualifiers
Has any prior history of cancer other than SGT
Has any MRI contra-indications
Has a history of known renal disease.
Has history of prior radiation to head and neck region
Trial design
Design model
Single group
Treatments tested in this trial
MRI
Diagnostic testYou are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: Salivary Gland TumorOther 1 intervention
Trial outcomes
Primary outcomes
1
Differentiation and Progression Free
Differentiation of malignant from benign neoplasms and progression free survival at 6 month starting from end of chemo-radiation treatment
Time frame
6 Month after the end of treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Abramson Cancer Center at Penn Medicine
Lead sponsor
University of Pennsylvania
Sponsor institution
McCabe Fund
Collaborator
Source ClinicalTrials.gov